Navigate
X
    QualityStocks
  • 18 years ago

HemoBioTech, Inc. (OTC BB: HMBT)

HemoBioTech, Inc. (OTC BB: HMBT), a biopharmaceutical company, is focused on developing HemoTech™, which may be the first viable substitute for human blood. HemoTech™, the company’s core product, is a bovine-hemoglobin (Hb) based human blood substitute that has the capability of replacing red blood cells in the human body. The company has an exclusive worldwide license for HemoTech, and intends to use its technology to meet the increasing demand for safe and inexpensive human blood substitute product around the world. For further information, visit the Company’s web site at www.hemobiotech.com.

Tags Rodman & Renshaw
Related Post
  1. QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection

    HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored,…

  2. QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Advancing Multi-Pronged Growth Strategy Across Beacon Mill and Swanson Gold Project

    Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising. LaFleur…

  3. QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) and Department of Commerce Sign Letter of Intent for $100 Million in CHIPS and Science Act Funding to Accelerate U.S. Leadership in Quantum Computing

    D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), the only dual-platform quantum computing company providing both annealing…